Clinical trials in intracerebral haemorrhage
Intracerebral haemorrhage (bleeding in the brain), also known as haemorrhagic stroke, leads to approximately 3 million deaths worldwide per year and leaves many survivors disabled and dependent on others. It is possible that administering medications to stop bleeding quickly after the onset of intracerebral haemorrhage might reduce the risk of people dying or becoming disabled. This talk will outline pre-clinical work assessing the role of Von Willebrand factor for reversing or reducing the effects of antiplatelet drugs (these are prescribed in patients who are at risk of heart attacks or blood clots, but they increase the risks from intracerebral haemorrhage) and discuss ongoing clinical trials of tranexamic acid and desmopressin aimed at reducing bleeding. It will also discuss research into newborn babies with a condition called Fetal and Neonatal AlloImmune Thrombocytopenia (FNAIT), who are at risk of intracerebral haemorrhage in the womb or shortly after birth.
Date: 12 February 2025, 12:00
Venue: John Radcliffe Academic, Headington OX3 9DU
Venue Details: NDCLS Seminar Room, Level 4 Academic Block, access via stairs near Cairns library
Speaker: Dr Michael Desborough
Organising department: Nuffield Division of Clinical Laboratory Sciences
Organiser: Dr Stephanie Jones (University of Oxford)
Organiser contact email address: stephanie.jones@ndcls.ox.ac.uk
Host: Prof Deborah Gill (University of Oxford )
Part of: NDCLS Seminar Series
Booking required?: Not required
Audience: Members of the University only
Editor: Stephanie Jones